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Abstract
Cytochrome P450 (P450) is a super-family of drug metabolizing enzymes. P450 enzymes have dual function; they can
metabolize drugs to pharmacologically inactive metabolites facilitating their excretion or biotransform them to
pharmacologically active metabolites which may have longer half-life than the parent drug. The variable pharmacological
response to psychoactive drugs typically seen in population groups is often not accountable by considering dissimilarities in
hepatic metabolism. Metabolism in brain specific nuclei may play a role in pharmacological modulation of drugs acting on
the CNS and help explain some of the diverse response to these drugs seen in patient population. P450 enzymes are also
present in brain where drug metabolism can take place and modify therapeutic action of drugs at the site of action. We
have earlier demonstrated an intrinsic difference in the biotransformation of alprazolam (ALP) in brain and liver, relatively
more a-hydroxy alprazolam (a-OHALP) is formed in brain as compared to liver. In the present study we show that
recombinant CYP3A43 metabolizes ALP to both a-OHALP and 4-hydroxy alprazolam (4-OHALP) while CYP3A4 metabolizes
ALP predominantly to its inactive metabolite, 4-OHALP. The expression of CYP3A43 mRNA in human brain samples
correlates with formation of relatively higher levels of a-OH ALP indicating that individuals who express higher levels of
CYP3A43 in the brain would generate larger amounts of a-OHALP. Further, the expression of CYP3A43 was relatively higher
in brain as compared to liver across different ethnic populations. Since CYP3A enzymes play a prominent role in the
metabolism of drugs, the higher expression of CYP3A43 would generate metabolite profile of drugs differentially in human
brain and thus impact the pharmacodynamics of psychoactive drugs at the site of action.
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Introduction
Cytochromes P450 (P450), the major class of drug metabolizing
enzymes, play an important role in determining therapeutic
efficacy through the conversion of drugs to their active metabolites
as well as detoxification to more hydrophilic metabolites that
facilitate rapid excretion [1]. Although liver is the major organ that
contributes to P450-mediated drug metabolism, biotransformation
at the site of action such as the brain by extrahepatic P450
enzymes is also an important determinant of therapeutic outcome
[2]. Previous studies from our laboratory and others have shown
that brain P450 enzymes from rodents [3],[4] and human brain
[5],[6] metabolize a variety of xenobiotics including drugs.
Further, the preferential localization of xenobiotic metabolizing
enzymes within specific cell types in these organs provides such
cells remarkable capability to metabolize foreign compounds
including drugs [1],[2],[7]. Metabolism of psychoactive drugs
directly in the brain may lead to local pharmacological modulation
at the site of action and result in variable drug responses [7]. The
focus of our current study is the human CYP3A family members
that contribute significantly to drug metabolism. Some of the
important substrates of CYP3A4 include macrolide antibiotics,
anti-arrhythmics, antidepressants, anxiolytics including alprazo-
lam, midazolam and diazepam [8], immune system modulators
and an array of calcium channel blockers. CYP3A4 is also
involved in the metabolism of endogenous steroidal substrates
including testosterone, progesterone, and androstenedione [9].
The human CYP3A subfamily consists of four functional genes,
CYP3A4, CYP3A5, CYP3A7, CYP3A43, and two pseudogenes,
CYP3A5P1 and CYP3A5P2. These genes are located in tandem
on chromosome 7 [10]. Expression of CYP3A genes is both tissue
and cell specific and exhibits inter-individual variation [11]. Of all
CYP3A subfamily members, CYP3A4 accounts for 60% of total
P450 content of adult human liver and metabolizes almost 50% of
the therapeutic drugs known [12]. CYP3A5 expression is one-fifth
of CYP3A4 levels in liver [13] although it has been reported to be
higher in African American population [14]. CYP3A7 is
predominately a fetal enzyme [15]. CYP3A43 is a recently
discovered member of this family [10],[16]. It is expressed at very
PLoS ONE | www.plosone.org 1 June 2008 | Volume 3 | Issue 6 | e2337low levels in liver, prostrate and testis and therefore has been
considered not to play a significant role in drug metabolism [17].
Alprazolam, a triazolobenzodiazepine, is an anti-anxiety drug
and one of the most widely prescribed benzodiazepines used in the
treatment of anxiety and panic disorders. In human liver
alprazolam is metabolized to hydroxylated metabolites by CYP3A
enzymes [18]. a-Hydroxy alprazolam (a-OHALP) is the minor but
pharmacologically active metabolite [19], while 4-hydroxy alpraz-
olam (4-OHALP) is the major and pharmacologically less active
metabolite [20]. ALP is also metabolized to its hydroxylated
metabolites by both rat and human brain microsomes indicating in
situ metabolism in the target organ. There is an intrinsic difference
in the biotransformation of alprazolam in brain and liver.
Although the presence of P450 enzymes in brain is one-tenth to
one-fifteen of liver [4], the metabolism of alprazolam by rat and
human brain microsomes to the active metabolite, (a-OHALP) is
relatively high [4]. Further, the amount of 4-hydroxy alprazolam
formed in rat brain is 3.2% of the concentration in liver, a-
hydroxy alprazolam concentration is 75% of the corresponding
level in liver [4]. We have now examined this biotransformation in
greater detail by studying the metabolism of alprazolam by
individual members of the CYP3A family; namely CYP3A4 and
CYP3A43, a relatively less studied enzyme, generated by
recombination. We have further quantitated the expression of
the CYP3A genes in human brain using quantitative real time
PCR and examined the correlation with the metabolites formed in
human brain microsomes.
Results
Constitutive Expression of CYP3A43 in human brain
Using RT-PCR, we amplified 85bp spanning partial exons 12–
13 of the 39 UTR of CYP3A43 such that there was no identity with
any other member of CYP3A subfamily using RNA from human
brain cortex (Fig 1a). This amplicon was cloned and used as
riboprobe for northern blot and localization using FISH. Northern
blot analysis using the antisense riboprobe revealed the expression
of CYP3A43 mRNA in human brain (Fig 1b). The molecular mass
of the transcript was approximately 1.6 Kb, which is similar to that
seen for hepatic CYP3A43. No signal was observed, when the
northern blot was hybridized with sense probe (data not shown).
Localization of constitutively expressed CYP3A43 mRNA in
human brain using fluorescence in situ hybridization clearly
demonstrates the differential expression of CYP3A43 mRNA in
different regions of human brain. CYP3A43 expression was
localized in cortical neurons (Fig 2a and b), pyramidal neurons of
the hippocampus (Fig 2h–m), granule cell layers of the dentate
gyrus (Fig 2n and o), and reticular neurons of the midbrain (Fig 2d).
In the cerebellum, granule cell layer showed intense fluorescent
labeling (Fig 2e); occasional staining was seen in the molecular layer
(Fig 2f), however, Purkinje cells showed no fluorescence (Fig 2f).
Relative expression of CYP3A4 and CYP3A43 in human
brain
CYP3A43 is expressed at relatively low levels in liver as
compared to CYP3A4, expression of CYP3A43 mRNA was about
0.1% of CYP3A4 in human liver samples (Fig 3b) while in the
brain CYP3A43 expression is relatively higher (Fig 3a). This was
confirmed by quantitative real time PCR (Fig 3b). Expression of
CYP3A4 and CYP3A43 in different tissues obtained at autopsy
from the same individuals showed that CYP3A43 was highest in
brain as compared to liver, kidney, lung, and heart (Fig 3c). Within
the CNS, CYP3A43 expression was highest in the pons and
cervical cord (Fig 3d). Out of the 40 samples of human brain
cortex obtained at autopsy from subjects of Indian origin that were
analyzed, 3 samples had 10–100 fold higher expression of
CYP3A43 compared to CYP3A4 while 2 showed a10 fold higher
degree of expression of CYP3A4, and 35 samples expressed both
the genes in equal amounts (Fig 4a and b). Amongst the 10
caucasian samples, CYP3A43 transcript levels were, on average,
170 fold higher than CYP3A4 (Fig 4c and d).
Cloning and expression of CYP3A4 and CYP3A43
The complete ORF of CYP3A4 and CYP3A43 were amplified by
RT-PCR using total RNA from human brain cortex (Fig 5a and b)
and cloned into mammalian expression vectors for expression in
COS-1 cells. CYP3A43 metabolized alprazolam equally to both a-
OHALP and 4-OHALP. CYP3A4, on the other hand metabolized
alprazolam principally to 4-OHALP (Fig 5c). No metabolite of
alprazolam was detected in cells transfected with vector alone or
vector containing the cDNA in reverse orientation (data not shown).
Western blotting confirmed the expression of full-length recombi-
nant CYP3A4 and CYP3A43 in COS-1 cells (Fig 5d).
Metabolism of alprazolam by human brain
Total membrane preparations from human brain cortex
metabolized alprazolam to its hydroxylated metabolites. Human
Figure 1. Constitutive expression of CYP3A43 mRNA in human
brain cortex. (a) Total RNA was extracted from human brain cortex of
2 subjects and the 39-UTR of CYP3A43 was amplified by RT-PCR (lanes 1
and 2). Lane N denoted reaction performed without template DNA. The
size of the PCR product was 85bp. (b) Total RNA from human brain
cortex was electrophoresed, transferred to positively charged nylon
membrane and hybridized with antisense riboprobe prepared using the
partial cDNA to CYP3A43. The mobility of 18S and 28S ribosomal RNA
on the agarose gel is indicated.
doi:10.1371/journal.pone.0002337.g001
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alprazolam to higher amounts of a-OHALP (Fig 6 a, g; b, h; c, i)
whereas, those that expressed higher levels of CYP3A4 formed more
4-OHALP (Fig 6 d, j; e, k). In addition, brain samples that expressed
both CYP3A4 and CYP3A43 in equal amounts metabolized
alprazolam to both a-OHALP and 4-OHALP (Fig 6 f, l). Pearson
analysis showed high degree correlation between expression levels of
CYP3A43 and the formation of a-OHALP (Fig 6m).
Relative expression of CYP3A family in human brain
The expression of both CYP3A4 and CYP3A43 were higher in
6 brain samples examined in comparison to CYP3A5, which was
detected only in four samples. CYP3A7, a fetal enzyme was not
detected in any of the sample analyzed (Fig 7a and b).
Splice variants of CYP3A43 and CYP3A4 in human brain
CYP3A43 has 13 exons. We amplified the exonic regions 1–5,
6–10, 11–13, and 6–13 (Fig 8a). The primers were designed on the
exon-exon boundaries such that intron inclusion in any splice
variant would be detected. RT-PCR amplification of exons 1–5
generated a product of the expected size (432bp; Fig 8b), however,
amplification of exons 6–10 generated two splice variants having
deletion of exon 7 (149bp) or exon 8 (128bp, Fig 8c). Both these
splice variants would potentially result in pre-mature stop codon.
Amplification of exons 11–13 generated a product with deletion of
exon 12 (126bp, Fig 8d). Finally we amplified exons 6–13 of
CYP3A43 and found a splice variant having deletion of exons 7
and 8 and partial inclusion of 121bp of intron 7. This variant
would potentially translate to a functional protein (Fig 8e). Similar
amplifications of the ORF of CYP3A4 did not yield any splice
variants (data not shown).
Discussion
Differential expression of CYP enzymes in organ and cell-
specific manner would contribute greatly to the pharmacodynam-
ics of drug action in the target organ. The metabolism of
alprazolam has been well studied in terms of the hepatic and
intestine metabolism [21]. Alprazolam is metabolized by CYP3A4
and CYP3A5 in the human liver [21],[22]. While CYP3A4
metabolizes alprazolam preferentially to 4-OHALP, metabolism
mediated by CYP3A5 leads to the formation of both a- and 4-
OHALP. Thus, the studies using human liver microsomes and
recombinant CYP3A4 and CYP3A5 have shown that these two
CYP enzymes are the major players in alprazolam metabolism.
However, it has been recently reported that 65–85% of Asians,
70% of Caucasians and 27–50% of African Americans carry the
CYP3A5*3 allele, which results in premature truncation and loss
Figure 2. Localization of CYP3A43 mRNA in human brain by fluorescence in situ hybridization. (a) Intense fluorescence was seen in
neuronal cell layers of frontal cortex. Differential localization was seen delineating the laminar architecture of the cortex. Bar=100 mm (b) Higher
magnification of cortical neurons (arrow). Bar=25 mm (c) Control section hybridized with sense probe did not show any fluorescence. Bar=100 mm
(d) Reticular neurons in the midbrain expressed CYP3A43 mRNA. Bar=100 mm (e) Fluorescent labelling of the granule cell layer (GL) in human
cerebellum. Sparse staining was observed in the molecular layer (ML). Bar=100 mm (f) Higher magnification of neurons of the granule cell layer in
cerebellum. Bar=25 mm (g) Control section hybridised with sense probe. Bar=100 mm (h) CYP3A43 expression was seen in pyramidal neurons of CA1
in the hippocampus. Bar=50 mm (i) Higher magnification of CA1 neurons. Bar=25 mm (j) Robust staining of the CA2 pyramidal cell layer (arrow) of
the hippocampus. Bar=50 mm (k) Higher magnification of pyramidal neurons in the CA2 subfield. Bar=25 mm (l) Intense fluorescence was seen in
the CA3 pyramidal neurons (arrow head) of the human brain. Bar=50 mm (m) Higher magnification of CA3 neurons (arrow head). Bar=25 mm (n)
Intense fluorescence was observed in the dentate gyrus. Staining of the interneurons of the hilus (arrow head) was also observed. Bar=100 mm (o)
Higher magnification of the granule cells in the dentate gyrus. Bar=25 mm (p) Control section of hippocampus hybridized with sense probe did not
show any fluorescence. Bar=100 mm
doi:10.1371/journal.pone.0002337.g002
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allele would be unable to metabolize ALP to a-OHALP [23].
CYP3A43 is a recently discovered P450 enzyme and has 75.7%
sequence identity with CYP3A4 and 75.6% with CYP3A5 [16].
CYP3A43 gene is upstream of CYP3A4 and is opposite in
orientation from all other 3A genes [16]. The expression of
CYP3A43 in human liver is 0.1% that of CYP3A4 and 2% that of
CYP3A5 [17]. Thus, the expression of CYP3A43 is relatively very
low in liver, lung, and kidney and therefore, it has been concluded
that CYP3A43 may not be a significant contributor to drug
metabolism in humans [17].
Earlier studies from our laboratory had shown that relatively
larger amount of a-OHALP is formed in human brain microsomes
[4]. We, therefore, examined the relative expression of CYP3A4,
CYP3A5, CYP3A7, and CYP3A43 in human brain cortex.
Interestingly, we found that the relative expression of CYP3A43
was significantly higher inbrain compared to the liver from the same
individual (Fig 3b). In the 3 samples analyzed, CYP3A43 expression
was 0.1% of CYP3A4 in liver while its expression was comparable to
CYP3A4 in human brain cortex (Fig 3b). When we analyzed the
relative expression of CYP3A43 and CYP3A4 in a larger set of 40
human brain autopsy tissues from the Indian population, we found
that unlike the liver [16], CYP3A43 and CYP3A4 were expressed in
equal amounts. In fact, in 3 out of 40 samples the expression of
CYP3A43 was several fold higher than that of CYP3A4 (Fig 4a). In
the 10 Caucasian samples analyzed CYP3A43 expression was
substantially higher than CYP3A4 (Fig. 4c and d).
We also analyzed the relative expression level of all the four 3A
genes in six brain samples and found that the expression of
CYP3A5 was significantly less than CYP3A4 and CYP3A43 in the
brain. Thus, its contribution to the generation of a-OHALP in
brain would be less than that of CYP3A43. While earlier studies
on the expression of CYP3A43 in human tissues have been done
in a semi-quantitative fashion, we provide the first quantitative
evidence for the expression of the CYP3A genes in human brain.
It is plausible that autolytic changes during the postmortem
interval could have contributed to this differential expression;
however, our earlier studies [24] have shown the stability of brain
RNA for up to 12 hr of postmortem interval.
Metabolism of ALP to its hydroxylated metabolites is often
indicative of reduced bioavailability of the parent drug since the
hydroxylated metabolites are unlikely to cross the blood brain
barrier. However, if these pharmacologically active metabolites
were to be generated in situ in the brain, they would exert
therapeutic action and potentially have a longer half life due to the
reduced clearance of the hydrophilic metabolites from the brain.
The reported relative potencies in benzodiazepine receptor
binding experiments and in animal models of seizure inhibition
are 0.20 and 0.66, respectively, for 4-OHALP and a-OHALP. It is
apparent that the a-OHALP is 3 times more potent that 4-
OHALP and therefore if generated in the brain it would exert
considerable therapeutic action.
We cloned and expressed recombinant CYP3A4 and CYP3A43
in COS-1 cells and examined the metabolism of ALP, in vitro.
ALP was metabolized predominantly to 4-OHALP by recombi-
nant CYP3A4, while recombinant CYP3A43 metabolized ALP to
both a and 4-OHALP in equal amounts (Fig 5c). In the present
study, we demonstrate the relatively higher expression of
Figure 3. Quantitative assessment of the expression of CYP3A4 and CYP3A43 in human brain cortex. (a) RT-PCR amplification of the
85bp of 39-UTR of CYP3A43 and 78bp of 39-UTR of CYP3A4 using human brain and liver RNA. (b) qRT-PCR analysis using human liver and brain RNA
(n=3) showed the relative higher expression of CYP3A43 in brain compared to liver from the same individuals. Quantitation of the relative expression
of CYP3A4 and CYP3A43 in (c) different human brain tissues (n=1) and (d) from different regions of the brain from same individual (n=3).
doi:10.1371/journal.pone.0002337.g003
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CYP3A43 to metabolize ALP to both 4-OHALP and a-OHALP.
This is the first demonstration of the functional significance of
CYP3A43 in terms of its ability to metabolize xenobiotics
including drugs, although a weak testosterone hydroxylation
activity has been demonstrated earlier [16]. However, the
presence of CYP3A43 protein in human brain is yet to be
demonstrated. The difficulty in generating antibodies to specific
CYP3A enzymes has been a limiting factor since these enzymes
show a high degree of sequence identity.
Domanski et al [16] had suggested that a high frequency of
alternatively spliced forms of CYP3A43 may be produced and
indeed, we have detected at least four alterative spliced forms in
the human brain (Fig 8), of these, three have premature
termination codon. One of them (having deletion of both the 7
and 8 exons and an insertion of 121bp of intron 7; Fig 8e) would
generate a complete open reading frame. This is currently being
characterized. The contribution of some of these spliced forms,
which are expressed as functional proteins need to be examined.
The CYP3A genes are differentially expressed in the brain but
they are also localized in distinct cell population and this would
further contribute to differential drug metabolism. For example,
CYP3A4 mRNA is predominantly localized in the Purkinje cell
layer (Fig 2) in the cerebellum while CYP3A43 expression is
completely lacking in this cell layer [4].
The presence of a relatively higher amount of CYP3A43 in
human brain may also contribute to the metabolism of other
psychoactive drugs that are metabolized by CYP3A enzymes.
While it is acknowledged that the measurement of gene expression
in the brain is relatively difficult and can only be done in autopsy
tissue, it would be helpful to incorporate the study of CYP3A43
mediated metabolism using the recombinant enzyme. This would
be particularly be useful in new drug development and would
provide a measure of the relative contribution of the parent drug
and the metabolites in situ in the target organ. It is to be seen
whether the differential expression of CYP3A enzyme observed in
the present study also extends to other members of the P450 family
and if indeed it is so; their contribution to the metabolism of
psychoactive drugs would be important determinants of the
pharmacodynamics of drug action in the brain.
Materials and Methods
Human Tissue
Human tissues were obtained from male and female traffic
accident victims with no known neurological or psychiatric
disorders through the Human Brain Tissue Repository, NIM-
HANS, India, in compliance with the ethical guidelines of the
Government of India. Autopsy was performed after obtaining
informed consent from the next of kin and the protocol for use of
autopsy tissue was cleared by the IRB of National Institute of
Mental Health and Neurosciences, Bangalore and National Brain
Research Centre, Manesar. For some of the experiments we also
obtained brain tissue from normal control subjects at autopsy from
the Washington DC and Northern Virginia Medical Examiners’
Offices (from the Section on Neuropathology Clinical Brain
Disorders Branch, GCAP, IRP, NIMH, NIH). Tissue was donated
with informed consent from the next of kin under NIMH protocol.
Figure 4. Expression of CYP3A43 and CYP3A4 in human brain samples from different population groups. Expression of CYP3A43 and
CYP3A4 in 6 individual samples of human brain cortex obtained from Indians depict the inter-individual variation (a). Expression of CYP3A43 and CYP3A4
averaged across 40 samples of human brain cortex from India (b). Comparison of CYP3A4 and CYP3A43 transcripts among 10 Caucasian brain samples (c)
demonstrated that on average (d) CYP3A43 expression is 170 fold higher than CYP3A4. All samples were normalized using 18S rRNA.
doi:10.1371/journal.pone.0002337.g004
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postmortem delay between death and autopsy was 5.5062.45 hr.
After autopsy, the brains were washed in ice-cold saline and
dissected into different regions based on standard anatomical
markings. Tissues were frozen and stored at 270uC immediately.
The tissues were thawed on ice prior to use. It was homogenized in
10 volumes of homogenization buffer consisting of 0.1M, pH 7.4
Tris-HCl (0.1M, pH 7.4) containing DTT (1 mM), KCl (1.15%
v/v), PMSF (0.1 mM), BHT (22 mM), aprotinin (0.001% w/v),
leupeptin (0.001% w/v) and glycerol (20% v/v). The buffer was
bubbled with nitrogen before use. The homogenate was
centrifuged at 100,000g for 1.5hr and the pellet was resuspended
in minimum amount of homogenization buffer, aliquoted, snap
frozen in liquid nitrogen and stored at 270uC until use.
RT-PCR amplification, cloning, and localization
Total RNA was isolated from samples of human brain cortex
using TRI reagent [25]. A region of the 39UTR of CYP3A43
consisting of 85bp [26] was amplified by RT-PCR using total
RNA from human brain. The amplicon was cloned and used to
generate sense and antisense riboprobes for northern blot analysis
and fluorescent in situ hybridization (FISH) experiments using T7
and T3 RNA polymerases, respectively. The complete open
reading frame (ORF) and partial exon-specific regions of CYP3A4
and CYP3A43 were also amplified using RT-PCR. All the PCR
products were verified by sequencing.
Northern blotting
Total RNA was separated electrophoretically and transferred to
a positively charged nylon membrane by capillary transfer [27],
UV cross-linked and hybridised with digoxigenin labelled
antisense riboprobes of the 39UTR of CYP3A43 prepared using
T7 and T3 RNA polymerases for generating sense and antisense
riboprobes respectively. The membrane was hybridised overnight
with digoxigenin labelled riboprobes at 52uC, washed, incubated
with antibody to digoxigenin Fab fragments conjugated with
alkaline phosphatase. The bands were visualized using a
chromogenic substrate for alkaline phosphatase.
Figure 5. Cloning and expression CYP3A43 and CYP3A4 and metabolism of alprazolam, in vitro by recombinant enzymes. The
complete open reading frame of CYP3A43 and CYP3A4 were amplified by RT-PCR using total RNA from four autopsy human brain samples. The
amplicons of 1586bp and 1512bp were generated for CYP3A4 and CYP3A43, respectively (a, and b, from lanes 1–4). M represents 100bp ladder and
Ne, the control reaction performed without template DNA. The amplicons were cloned into pcDNA 3.1 for expression in COS-1 cells. (c) Recombinant
CYP3A43 metabolized alprazolam to a-OHALP and 4-OHALP in similar amounts (26 pmoles/min/mg protein), while recombinant CYP3A4 metabolized
alprazolam only to 4-OHALP. The values are mean ISD (n=3 independent experiments). (d) Immunoblot of recombinant CYP3A43 and CYP3A4
normalized using b-tubulin.
doi:10.1371/journal.pone.0002337.g005
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Regions from human brain (cortex, cerebellum, midbrain and
hippocampus) were dissected out and fixed in buffered paraformal-
dehyde. The tissue was processed for paraffin embedding and serial
sections (8–10 mm thick) were cut under RNase-free conditions.
Sections were dewaxed, hydrated in graded ethanol; acetylated and
treated with proteinase K. The sections were rinsed in phosphate-
buffered saline (PBS) and dehydrated using graded ethanol.
Digoxigenin-labelled sense (for control sections) and antisense cRNA
probesweresynthesized from cDNAtoCYP3A43-39UTR usingT3
and T7 RNA polymerases. Sections were hybridised overnight at
55uC with the sense and antisense probes. After hybridisation, the
sections were washed, blocked with 0.5% (w/v) bovine serum
albumin and incubated with antibody to digoxigenin Fab fragments
conjugated to horseradish peroxidase. After washing, the sections
were incubated with biotinylated tyramide (NEN Life sciences
Products, USA) followed by FITC labelled streptavidin. Finally the
sections were washed, dried and mounted prior to examination
under a fluorescence microscope.
Quantitative real-time PCR
The relative expression of CYP3A4, CYP3A5, CYP3A7, and
CYP3A43 was quantitated in human brain cortex by real-time
PCR using the primer sets reported by Williams et al. 2004 [26].
iQ SYBR green Supermix from Biorad was used. The conditions
for real-time PCR were as follows: 95uC for 3 min (1 cycle), 94uC
for 20 sec, 62uC for 30 sec, and 72uC for 30 sec (40 cycles), 72uC
for 3 min (1cycle). The real-time PCR results were analyzed using
the iCycler Thermal Cycler software (Biorad). qRT-PCR for
Caucasian-American Samples were done using an ABI Prism 7700
sequence detection system (Applied Biosystems, Foster City, CA)
housed in the Quantitative Genomics Lab Core facility at the
University of Texas Health Science Center, Houston. Amplifica-
tion for each assay was carried out at 95uC for 1 minute, followed
by 40 cycles of a 12 second step at 95uC and a 30 second step at
60uC. TaqmanH style primer and probe sets were designed to
overlap the exon/exon junctions of mRNA using the Primer
Express software (Applied Biosystems). The probes contain a 59 6-
FAM (5-carboxyfluorescein) and a 39 TAMRA (5-carboxytetra-
methylrhodamine). The sequences for the primer and probe sets
used for the CYP3A4 and CYP3A43 assays can be found in the
previous publication by Williams et al. 2004 [26]. All reactions
were normalized with 18S rRNA as internal control and all
reactions were carried out in triplicates.
Experiments with recombinant CYP3A4 and CYP3A43
Complete ORFs of CYP3A4 and CYP3A43 were cloned into
mammalian expression vector and transiently transfected into
COS-1 cells. Cells transfected with vector alone were used as
control. After antibiotic selection, cells were harvested after 48hrs
in cold DMEM media. The cells were centrifuged at 1500g for
10 min at 4uC. The cell pellet was washed twice with the
homogenization buffer consisting of Tris-HCl (0.1M, pH 7.4)
containing DTT (1 mM), KCl (1.15% v/v), PMSF (0.1 mM),
BHT (22 mM), aprotinin (0.001% w/v), leupeptin (0.001% w/v)
and glycerol (20% v/v). The buffer was bubbled with nitrogen
before use. Finally, the pellet was resuspended in minimum
Figure 6. Metabolism of alprazolam to a-OHALP and 4-OHALP
by human brain, in vitro. The expression levels of CYP3A4 and
CYP3A43 were compared with the rates of formation of a-OHALP and 4-
OHALP in samples of cortex obtained from 6 human brain subjects.
Subjects represented in (a, b, c) expressed high levels of CYP3A43 and
relatively higher amounts of a-OHALP was formed compared to 4-
OHALP (g, h, i). Subjects (d, e) expressed high levels of CYP3A4 and
formed relatively higher amounts of 4-OHALP (j, k). Subject (f) showed
similar levels of expression CYP3A4 and CYP3A43 which was reflected in
the amount of hydroxylated metabolite formed. Pearson correlation
analysis showed high degree of correlation between the expression
levels of CYP3A43 and amounts of a-OHALP formed (m; r=0.74).
doi:10.1371/journal.pone.0002337.g006
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Elvehjem homogenizer with 20 up and down strokes. The cell
homogenate prepared as above was aliquoted and kept frozen at
270uC and used to study the metabolism of alprazolam. For
immunoblotting, antibody to CYP3A was procured from BD
Gentest; NJ, USA was used.
Figure 7. Relative expression of functional genes of CYP3A subfamily members in human brain samples. (a) The levels of CYP3A4,
CYP3A5, CYP3A7, and CYP3A43 mRNA were quantified by qRT-PCR in the 6 human brain subjects. The expression of CYP3A5 was significantly lower
then that of CYP3A4 and CYP3A43 and was detected only in four out of six samples. CYP3A7 was not detected in any of the subjects. (b) The average
of the six samples analyzed.
doi:10.1371/journal.pone.0002337.g007
Figure 8. Amplification of exonic regions of the ORF of CYP3A43 and CYP3A4 mRNA by RT-PCR. (a) The schematic representation of 13
exons of CYP3A43 along with their splice variants detected by RT-PCR is depicted. (b) A 432bp amplicon was amplified spanning the exons 1–5 (lanes
1 and 2). (c) Two amplicons (594bp and 450bp) were generated when exons 6–10 were amplified (lanes 1 and 2). The 594bp product was the
expected amplicon while the other amplicon (450bp) was a mixture of two PCR products of which one had a deletion of exon 7 and other had a
deletion of exon 8. (d) Amplification of the region spanning exons 11–13 gave two amplicons of sizes 486bp and 350bp. The 486bp product was the
expected size while 350bp product represented a splice variant that had the deletion of exon 12. (e) Amplification of exons 6–13 generated an
amplicon (950bp) representing a splice variant having deletion of both exon 7 and 8 and partial inclusion of 121bp intron 7.
doi:10.1371/journal.pone.0002337.g008
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Human brain total membrane preparations (containing micro-
somal and mitochondrial protein) from human brain cortex
containing microsomal and mitochondrial protein and total lysates
from cells expressing recombinant CYP3A4 and CYP3A43 cells
preparations (1 mg/ml protein) were preincubated with alprazo-
lam (1 mM) at 37uC for 4 min. The reactions were initiated by
addition of NADPH (5 mM) and purified liver NADPH-
cytochrome P450 reductase (1 unit). The reactions were
terminated after 30 min by the addition of NH4OH (0.1%, v/v).
The incubations were extracted thrice by using dichloromethane
(2 ml), vortexed, centrifuged at 4000 g (5 min) and the lower
organic phase was pooled and evaporated under nitrogen gas at
45uC. The residue was dissolved in 0.4 ml of the HPLC mobile
phase consisting of potassium phosphate buffer (50 mM, pH 9.0)
containing acetonitrile (30% v/v) filtered and injected into an
HPLC column consisting of (SUPELCOSIL, (LC-C18 column) at
the flow rate of 1 ml per min
21. Blank reactions did not contain
NADPH. Formations of metabolites were detected using a UV
detector set at 224 nm. Standards 4-hydroxy alprazolam, a-
hydroxy alprazolam, and alprazolam were used for quantification
of metabolites.
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